A research team has developed a diagnostic system that uses artificial intelligence (AI) to accurately identify the type of ...

The US Food and Drug Administration (FDA) has granted 510 (k) clearance to PathAI for its digital pathology image management ...

A research team led by Haruyo Yamamoto, Chisa Nakashima, and Atsushi Otsuka from Department of Dermatology, Kindai University Faculty of Medicine, in collaboration with the Faculty of Engineering at ...

Journey Medical to Join Russell 2000® and Russell 3000® Indexes. SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the ...

Mortality rates associated with calciphylaxis are lower than previously observed, with rates of 28.88% at 1-year and 29.92% at 2-years.

The abundance in Black skin of melanin, the pigment that gives skin its color, offers extra protection from damaging ...

How DERM works. For lesions identified as pre-cancerous or cancerous, an NHS dermatologist reviews the case virtually and determines the appropriate management plan. For patients with black or brown ...

DERM (Deep Ensemble for Recognition of Malignancy), which was approved in the UK as a Class IIA medical device in 2022, analyses images to assess and triage skin lesions, and may be able to refer ...

DERM provides a suspected diagnosis and triages the case. Patients with benign lesions may be redirected to non-urgent pathways and receive written safety-netting advice. Suspicious lesions are ...

As a direct result of AADA advocacy, Regence Blue Cross Blue Shield (BCBS) rescinded its modifier 25 payment reduction policy ...

A research team led by Haruyo Yamamoto, Chisa Nakashima, and Atsushi Otsuka from Department of Dermatology, Kindai University Faculty of Medicine, in ...

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.